Moreover, a key finding from our study demonstrated that the increase of tumor-infiltrating Ag-specific CD8+ T cells with KLRG1+ effector phenotype can play a role in eliciting tumor clearance in the combination Vax/aGITR/aPD-1 therapy. Here, CD8A is linked to neoplasm.